Form 4 for PBYI PUMA BIOTECHNOLOGY, INC.
Accepted 2022-12-12 00:00:00 ET · period of report 2022-12-12 · accession 0001437749-22-028940 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-12-12 | 2022-12-12 | PBYI | AUERBACH ALAN H | Pres, CEO, Dir, 10% | A - Grant | $4.40 | +568.2K | 6.88M | +9% | +$2.50M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-12 | A | A | 568,181 | $4.40 | 6,879,879 | D | — | — | (F1) On December 9, 2022, the Issuer entered into a Securities Purchase Agreement with the Reporting Person, pursuant to which these shares were purchased by the Reporting Person at the closing on December 12, 2022 for $4.40 per share. |